Меню
Набор скоро начнётся NCT06581107

Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures

Без фазы С лечением Lung Cancer Thoracic Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation.
Кому может быть актуально
Состояния в реестре: Lung Cancer, Thoracic Cancer. Базовые параметры: 18 лет — 75 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Validate the Feasibility and Safety of the Robot System by Investgating the CT-fluoroscopy Guidance in Percutaneous Lung Cryablation Procedures of Participants With Lung Cancer

Обзор

This study aims to investigate whether the interventional robot can be well and safely used for percutaneous lung cryoablation in patients with lung cancer. The robot allows radiologists to remotely control the needle insertion process under CT fluoroscopy guidance. The main questions this study aims to answer are: 1. Whether the robot-assisted Cryoablation method can achieve complete the coverage of preoperatively planned ablation areas; 2. Whether the robot-assisted Cryoablation method can improve the success rate for radiologists to insert the needle into the target lesion area without additional needle adjustment; 3. Whether the robot-assisted Cryoablation method can reduce puncture time, ablation time and procedure time; 4. Whether the robot-assisted Cryoablation method can decrease the patient's complication occurrence rate; 5. Whether the robot-assisted Cryoablation method can obtain decent Evaluation of system performance.

Подробное описание

Lung cancer is the leading cause of morbidity and mortality of malignant tumors.

The surgical resection of lung lobes is the standard treatment for stage I non-small cell lung cancer (NSCLC), with proven long-term cure rates and survival. However, more than 20% of patients are not eligible for surgical treatment due to comorbidities or poor underlying lung reserve.

With the development of minimally invasive interventional field, lung cancer cryoablation has also become an established tool for the treatment of early stage lung cancer and palliative treatment of advanced lung cancer in recent years.

However, the image-guidance cryoablation method still faces the following challenges:

1. Lack of real-time and accurate information during the needle insertion process, including puncture force, needle deformation, soft tissue deformation, and needle arrival position; 2. Multiple scans during the puncture are needed to determine whether the needle has successfully reached the target area, which leads to prolonged operation time, easily induces complications and increases the radiation dose to the physicians. 3. The accuracy of needle insertion is highly affected by the patient's respiration movement causing the multi-directional nonlinear displacement and deformation of tissues and organs (movement, rotation, etc.), resulting in the drift of the tumour position. Eventually, it is difficult for radiologists to reach the target position, resulting in insufficient ablation areas and increased probability of cancer recurrence. 4. The physiological trembling of the radiologist's hand will reduce the accuracy of puncture, and even lead to complications such as bleeding and pneumothorax 5. The procedure is highly dependent on the ability and experience of radiologists.

Вмешательства

  • Процедура CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation
    During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are rec

Первичные конечные точки

  • Technical success rate [Срок оценки: The day of the procedure]
Вторичные конечные точки (7)
  • The number of needle adjustments [Срок оценки: The day of the procedure]
  • Number of cryoprobes used [Срок оценки: The day of the procedure]
  • Puncture time [Срок оценки: The day of the procedure]
  • Ablation time [Срок оценки: The day of the procedure]
  • Procedure time [Срок оценки: The day of the procedure]
  • Evaluation of system performance [Срок оценки: The day of the procedure]
  • Compliations [Срок оценки: 7±1 days postoperatively/on the day of discharge (whichever comes first).]

Критерии участия

Критерии включения

  • Participants suffering from lung cancer and judged by the investigator to be indicated for cryoablation procedures;
  • Participants voluntarily participate in this clinical study and sign the informed consent form;
  • Participants cannot undergo surgical treatment due to contraindications to surgical resection of lung cancer;
  • Participants can understand the study and cooperate with the study procedures, and are able to carry out follow-up observation as required.

Критерии исключения

  • Participants have diffuse lesions in both lungs that cannot be improved by ablative therapy;
  • Participants suffer from extensive pleural metastases with massive pleural effusion;
  • Participants have tumors adjacent to the mediastinal blood vessels, contrast allergy, or inability to cooperate, which makes it difficult to choose the route of needle insertion;
  • Participants with lesions encircling blood vessels where ablation may lead to severe bleeding;
  • Participants with severely impaired lung function, with maximal ventilation <40%;
  • Participants with a low platelet count and severe coagulation abnormalities who cannot tolerate the procedure (anticoagulant therapy and/or anticoagulant medication should be discontinued for more than 1 week prior to ablation therapy);
  • Participants with poor general condition (multiple metastases throughout the body, severe infections, high fever), obvious malignant disease, severe insufficiency of vital organ function, severe anemia, and disorders of nutritional metabolism that cannot be improved in the short term;
  • Allergy to contrast media or anesthetics;
  • Pregnant or breastfeeding women, or those who plan to have children during the clinical study;
  • Participants with known addiction to drugs, alcohol, etc.;
  • Participants with psychiatric disorders who have no self-control and are unable to communicate clearly;
  • Participants who have participated in other drug, biologic, or medical device clinical studies without meeting the primary study endpoint timeframe prior to enrollment in this study;
  • Any other conditions that the investigator deems unsuitable for participation in this clinical study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • Tianjin Medical University, Cancer Institute & Hospital — Тяньцзинь

Идентификаторы

NCT: NCT06581107 · ZRIR-002-24-06

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗